NVAX250110C6500
- 3.08
- +0.56+22.22%
Novavax Newsroom
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $22
Novavax's Strategic Partnerships and Pipeline Developments Drive Buy Rating With Promising Long-term Growth Potential
Novavax Analyst Ratings
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $22
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $22
B. Riley Adjusts Novavax Price Target to $22 From $26, Maintains Buy Rating
Strategic Transformation and Growth Prospects: Mayank Mamtani's Buy Rating on Novavax
Novavax Analyst Ratings
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $9
Novavax's Market Share and Pipeline Uncertainties Lead to Sell Rating
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Cuts Target Price to $12
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
Novavax Analyst Ratings
Novavax Gains Competitive Edge With FDA Clearance and Strategic Collaborations, Earning Buy Rating
J.P. Morgan Maintains Novavax(NVAX.US) With Sell Rating, Maintains Target Price $9
Novavax Analyst Ratings
Jefferies Maintains Novavax(NVAX.US) With Buy Rating, Cuts Target Price to $25
Cautious Optimism for Novavax Amid Clinical Hold Challenges
Jefferies Cuts Novavax's Price Target to $25 From $31, Buy Rating Maintained